Impatto del COVID-19 sulla mortalità e sugli esiti critici in varie condizioni di immunodeficienza: una meta-analisi
Barra laterale dell'articolo
Contenuto principale dell'articolo
Abstract
Introduzione:
Il COVID-19 ha impatti variabili su diverse popolazioni immunocompromesse, rendendo necessaria un’analisi completa dei suoi effetti su questi gruppi.
Obiettivi:
Valutare l’impatto del COVID-19 sulla mortalità e sugli esiti critici tra diverse popolazioni immunocompromesse attraverso una meta-analisi degli studi esistenti.
Metodi:
Sono stati sintetizzati i dati di 14 studi, coinvolgendo 6.094 pazienti. Le proporzioni di mortalità aggregate sono state calcolate utilizzando sia modelli a effetto comune che a effetti casuali. Sono state condotte analisi per sottogruppi per diverse condizioni di immunocompromissione, esaminando i tassi di mortalità, i ricoveri in terapia intensiva e le necessità di ventilazione meccanica. Sono state eseguite analisi di sensibilità per valutare la robustezza dei risultati.
Risultati:
La proporzione di mortalità aggregata era 0,12 (IC 95%: 0,11, 0,12) nel modello a effetto comune e 0,06 (IC 95%: 0,04, 0,10) nel modello a effetti casuali, con una significativa eterogeneità (I2 = 98%).
I pazienti con cancro ematologico hanno mostrato la mortalità più alta (0,29, IC 95%: 0,25, 0,33).
I tassi di ricovero in terapia intensiva erano più alti per le malattie reumatiche autoimmuni e i cancri ematologici. La ventilazione meccanica era più frequentemente richiesta nelle malattie reumatiche autoimmuni e nei pazienti con tumori solidi.
Discussione:
Lo studio ha rivelato una sostanziale variabilità negli esiti del COVID-19 tra i diversi gruppi immunocompromessi. L’alta eterogeneità osservata sottolinea la necessità di approcci di gestione clinica specifici per ogni condizione. Le analisi di sensibilità hanno confermato la robustezza dei risultati.
Conclusione:
Questa meta-analisi fornisce intuizioni critiche sull’impatto differenziale del COVID-19 su varie popolazioni immunocompromesse, sottolineando l’importanza di strategie cliniche su misura per questi gruppi vulnerabili.
Downloads
Dettagli dell'articolo
Questo lavoro è fornito con la licenza Creative Commons Attribuzione - Non commerciale 4.0 Internazionale.
Riferimenti bibliografici
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72-314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648. PMID: 32091533.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3. PMID: 32171076; PMCID: PMC7270627.
Hoffmann C, Casado JL, Härter G, et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2020;21(10):668-674. doi:10.1111/hiv.13037. PMID: 32845023.
Docherty AB, Harrison EM, Green CA, et al. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369. doi:10.1136/bmj.m1985. PMID: 32444460; PMCID: PMC7243036.
Fox TA, Troy-Barnes E, Kirkwood AA, et al. Response to "Impact of immunosuppression on mortality in critically ill COVID-19 patients’. Br J
Haematol. 2020;191(1):144-145. doi:10.1111/bjh.16951. PMID: 32785836.
Baek MS, Lee MT, Kim WY, et al. COVID-19 related outcomes in immunocompromised patients: A nationwide study in Korea. PLoS One. 2021;16(10).
doi:10.1371/journal.pone.0257641. PMID: 34597325; PMCID: PMC8486114.
Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8). doi:10.1016/S2214-109X(20)30264-3. PMID: 32553130; PMCID:PMC7295519.
Doney KC, Mielcarek M, Stewart FM, et al. Hematopoietic cell transplantation
after solid organ transplantation. Biol Blood Marrow Transplant.
;21(12):2123-2128. doi:10.1016/j.bbmt.2015.08.004. PMID: 26271193.
Chiaretti S, Bonifacio M, Agrippino R, et al. COVID-19 infection in acute
lymphoblastic leukemia over 15 months of the pandemic. Haematologica.
;107(8):1955-1959. doi:10.3324/haematol.2021.280289. PMID:
; PMCID: PMC9335088.
Turtle LC, Thorpe M, Drake TM, et al. Outcome of COVID-19 in hospitalised
immunocompromised patients: an analysis of the WHO ISARIC CCPUK
prospective cohort study. PLoS Med. 2023;20(1). doi:10.1371/journal.
pmed.1004130. PMID: 36670859; PMCID: PMC9862367.
Wei L, Wang W, Chen D, et al. Dysregulation of the immune response affects
the outcome of critical COVID-19 patients. J Med Virol. 2020;92(10):2768-
doi:10.1002/jmv.26187. PMID: 32592470.
Shabani S, Cheraghi P, Ghaffari-Nazari H, et al. COVID-19 adverse outcomes
in immunocompromised patients. Int J Cancer Manag. 2023;16(3):1-8.
doi:10.5812/ijcm.124579.
Haidich AB. Meta-analysis in medical research. Hippokratia. 2010;14(Suppl
:29-37. PMID: 21487488; PMCID: PMC3049418.
Borenstein M, Hedges LV, Higgins JP, et al. Introduction to Meta-Analysis. John
Wiley & Sons; 2009. doi:10.1002/9780470743386.
García-Suárez J, de la Cruz J, Cedillo Á, et al. Impact of hematologic malignancy
and type of cancer therapy on COVID-19 severity and mortality: lessons from
a large population-based registry study. J Hematol Oncol. 2020;13(1):133.
doi:10.1186/s13045-020-00970-7. PMID: 33032660; PMCID: PMC7542567.
Haggenburg S, Hofsink Q, Lissenberg-Witte BI, et al. Antibody response
in immunocompromised patients with hematologic cancers who received
a 3-dose mRNA-1273 vaccination schedule for COVID-19. JAMA Oncol.
;8(10):1477-1483. doi:10.1001/jamaoncol.2022.3227. PMID: 35951338;
PMCID: PMC9372904.
Passamonti F, Nicastri E, Di Rocco A, et al. Management of patients with
lymphoma and COVID-19: narrative review and evidence-based practical
recommendations. Hematol Oncol. 2023;41(1):3-15. doi:10.1002/hon.3086.
PMID: 36251481; PMCID: PMC9874581.
Finelli C, Parisi S. The clinical impact of COVID-19 epidemic in the hematologic
setting. Adv Biol Regul. 2020;77:100742. doi:10.1016/j.jbior.2020.100742.
PMID: 32773103; PMCID: PMC7364141.
Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients
of hematopoietic cell transplantation. J Clin Invest. 2020;130(12):6656-6667.
doi:10.1172/JCI141777. PMID: 32897885; PMCID: PMC7685738.
Dhodapkar MV, Dhodapkar KM, Ahmed R, et al. Viral immunity and
vaccines in hematologic malignancies: implications for COVID-19. Blood
Cancer Discov. 2021;2(1):9-12. doi:10.1158/2643-3230.bcd-20-0177. PMID:
; PMCID: PMC8486288.
Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know
so far. Clin Infect Dis. 2021;72(2):340-350. doi:10.1093/cid/ciaa863. PMID:
; PMCID: PMC7337668.
Haddaway NR, Page MJ, Pritchard CC, et al. PRISMA2020: an R package
and Shiny app for producing PRISMA 2020-compliant flow diagrams, with
interactivity for optimised digital transparency and Open Synthesis. Campbell
Syst Rev. 2022;18(1). doi:10.1002/cl2.1230.
Al-Adhoubi NK, Ali M, Wahshi HA, et al. COVID-19 mortality in patients
with rheumatic diseases: a real concern. Curr Rheumatol Rev. 2022;18(3):234-
doi:10.2174/1573397118666220412114514. PMID: 35418287.
Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory
syndrome coronavirus 2 replication in an immunocompromised patient. J
Infect Dis. 2021;223(1):23-27. doi:10.1093/infdis/jiaa666. PMID: 33089317;
PMCID: PMC7797758.
Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune
systemic diseases: report of a large Italian patients series. Clin Rheumatol.
;39(11):3195-3204. doi:10.1007/s10067-020-05334-7. PMID: 32852623;
PMCID: PMC7450255.
Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of Coronavirus Disease
(COVID-19) related hospitalization among people with human
immunodeficiency virus (HIV) in the ISARIC World Health Organization
(WHO) Clinical Characterization Protocol (UK): A prospective observational
study. Clin Infect Dis. 2021;73(7). doi:10.1093/cid/ciaa1605. PMID: 33095853;
PMCID: PMC7665382.
Gervasoni C, Meraviglia P, Riva A, et al. Clinical features and outcomes of
patients with human immunodeficiency virus with COVID-19. Clin Infect Dis.
;71(16):2276-2278. doi:10.1093/cid/ciaa579. PMID: 32407467; PMCID:
PMC7239244.
Karakoc Aydiner E, Bilgic Eltan S, Babayeva R, et al. Adverse COVID-19
outcomes in immune deficiencies: inequality exists between subclasses. Allergy.
;77(1):282-295. doi:10.1111/all.15025. PMID: 34314546; PMCID:
PMC8441734.
Klineova S, Farber RS, DeAngelis T, et al. Vaccine-breakthrough
SARS-CoV-2 infections in people with multiple sclerosis and related
conditions: An observational study by the New York COVID-19 Neuro-
Immunology Consortium (NYCNIC-2). Mult Scler. 2023;29(8):990-1000.
doi:10.1177/13524585231185246. PMID: 37431628; PMCID: PMC10333977.
Marques NP, Silveira DMM, Marques NCT, et al. Cancer diagnosis in Brazil
in the COVID-19 era. Semin Oncol. 2021;48(2):156-159. doi:10.1053/j.
seminoncol.2020.12.002. PMID: 33478743; PMCID: PMC7789866.
Meyts I, Bucciol G, Quinti I, et al. Coronavirus disease 2019 in patients with
inborn errors of immunity: an international study. J Allergy Clin Immunol.
;147(2):520-531. doi:10.1016/j.jaci.2020.09.010. PMID: 32980424;
PMCID: PMC7832563.
Moreno-Torres V, Mendoza C, Mellor-Pita S, et al. Systemic autoimmune
diseases in patients hospitalized with COVID-19 in Spain: a nationwide
registry study. Viruses. 2022;14(8):1631. doi:10.3390/v14081631. PMID:
; PMCID: PMC9394472.
Pablos JL, Abasolo L, Alvaro-Gracia JM, et al. Prevalence of hospital
PCR-confirmed COVID 19 cases in patients with chronic inflammatory
and autoimmune rheumatic diseases. Ann Rheum Dis. 2020;79(9):1170-
doi:10.1136/annrheumdis-2020-217763. PMID: 32532753; PMCID:
PMC7299645.
Schulz E, Hodl I, Forstner P, et al. CD19+IgD+CD27- naive B cells as predictors
of humoral response to COVID-19 mRNA vaccination in immunocompromised
patients. Front Immunol. 2021;12:803742. doi:10.3389/fimmu.2021.803742.
PMID: 34950155; PMCID: PMC8688243.
Vera-Lastra O, Cimé-Aké E, Navarro A, et al. Risk factors and outcomes for
COVID-19 in autoimmune inflammatory diseases during the SARS-CoV-2
pandemic: a comparative study. Isr Med Assoc J. 2022;24(5):299-305. PMID:
Wu X, Wu G, Ma P, et al. Immediate and long-term outcomes after treat-all
among people living with HIV in China: an interrupted time series analysis.
Infect Dis Poverty. 2023;12(1):73. doi:10.1186/s40249-023-01119-7. PMID:
; PMCID: PMC10424386.